Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
ACS Omega ; 9(8): 8687-8708, 2024 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-38434894

RESUMO

The use of carbon nanotubes (CNTs), which are nanometric materials, in pathogen detection, protection of environments, food safety, and in the diagnosis and treatment of diseases, as efficient drug delivery systems, is relevant for the improvement and advancement of pharmacological profiles of many molecules employed in therapeutics and in tissue bioengineering. It has contributed to the advancement of science due to the development of new tools and devices in the field of medicine. CNTs have versatile mechanical, physical, and chemical properties, in addition to their great potential for association with other materials to contribute to applications in different fields of medicine. As, for example, photothermal therapy, due to the ability to convert infrared light into heat, in tissue engineering, due to the mechanical resistance, flexibility, elasticity, and low density, in addition to many other possible applications, and as biomarkers, where the electronic and optics properties enable the transduction of their signals. This review aims to describe the state of the art and the perspectives and challenges of applying CNTs in the medical field. A systematic search was carried out in the indexes Medline, Lilacs, SciELO, and Web of Science using the descriptors "carbon nanotubes", "tissue regeneration", "electrical interface (biosensors and chemical sensors)", "photosensitizers", "photothermal", "drug delivery", "biocompatibility" and "nanotechnology", and "Prodrug design" and appropriately grouped. The literature reviewed showed great applicability, but more studies are needed regarding the biocompatibility of CNTs. The data obtained point to the need for standardized studies on the applications and interactions of these nanostructures with biological systems.

2.
Curr Top Med Chem ; 21(13): 1186-1197, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34323186

RESUMO

BACKGROUND: Tuberculosis (TB) has been a challenging disease worldwide, especially for the neglected poor populations. Presently, there are approximately 2 billion people infected with TB worldwide and 10 million people in the world fell ill with active TB, leading to 1.5 million deaths. INTRODUCTION: The classic treatment is extensive and the drug- and multi-drug resistance of Mycobacterium tuberculosis has been a threat to the efficacy of the drugs currently used. Therefore, the rational design of new anti-TB candidates is urgently needed. METHODS: With the aim of contributing to face this challenge, 78 compounds have been proposed based on SBDD (Structure-Based Drug Design) strategies applied to target the M. tuberculosis phosphopantetheine adenylyltransferase (MtPPAT) enzyme. Ligand-Based Drug Design (LBDD) strategies were also used for establishing Structure-Activity Relationships (SAR) and for optimizing the structures. MtPPAT is important for the biosynthesis of coenzyme A (CoA) and it has been studied recently toward the discovery of new inhibitors. RESULTS: After docking simulations and enthalpy calculations, the interaction of selected compounds with MtPPAT was found to be energetically favorable. The most promising compounds were then synthesized and submitted to anti-M. tuberculosis and MtPPAT inhibition assays. CONCLUSION: One of the compounds synthesized (MCP163), showed the highest activity in both of these assays.


Assuntos
Antituberculosos/farmacologia , Desenho de Fármacos , Inibidores Enzimáticos/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Nucleotidiltransferases/antagonistas & inibidores , Antituberculosos/síntese química , Antituberculosos/química , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Testes de Sensibilidade Microbiana , Estrutura Molecular , Mycobacterium tuberculosis/enzimologia , Nucleotidiltransferases/metabolismo
3.
Front Chem ; 9: 734983, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-35237565

RESUMO

Hydroxymethylation is a simple chemical reaction, in which the introduction of the hydroxymethyl group can lead to physical-chemical property changes and offer several therapeutic advantages, contributing to the improved biological activity of drugs. There are many examples in the literature of the pharmaceutical, pharmacokinetic, and pharmacodynamic benefits, which the hydroxymethyl group can confer to drugs, prodrugs, drug metabolites, and other therapeutic compounds. It is worth noting that this group can enhance the drug's interaction with the active site, and it can be employed as an intermediary in synthesizing other therapeutic agents. In addition, the hydroxymethyl derivative can result in more active compounds than the parent drug as well as increase the water solubility of poorly soluble drugs. Taking this into consideration, this review aims to discuss different applications of hydroxymethyl derived from biological agents and its influence on the pharmacological effects of drugs, prodrugs, active metabolites, and compounds of natural origin. Finally, we report a successful compound synthesized by our research group and used for the treatment of neglected diseases, which is created from the hydroxymethylation of its parent drug.

4.
Int J Pharm ; 568: 118498, 2019 Sep 10.
Artigo em Inglês | MEDLINE | ID: mdl-31301465

RESUMO

Water solubility has been identified as a critical parameter and the main responsible by affecting poor performance of oral drug delivery. Poorly soluble drugs can originate unsatisfactory ADME properties leading to low oral bioavailability, insufficient chemical stability, low half-life, fast pre-systemic metabolism and difficulties in formulation. In this context, the prodrug design is an alternative in order to improve physicochemical, biopharmaceutical and pharmacokinetic properties such as permeability, solubility, bioavailability, chemical stability and metabolism of molecules presenting poor drug-like properties. In this article we highlight the importance of the prodrug design in the early stages of drug discovery and development process, in an attempt to diminish the attrition rate and end up falling into the valley of death. Selected examples of this strategy are provided in this review and they are classified by some basic functional groups that are amenable to the prodrug approach with the aim of increasing aqueous solubility of poorly water-soluble compounds. Over the past decade, the number of approved prodrugs is considerable among all drugs launched in the market, emphasizing the importance of this tool on drug design. It is reported that 10% of all marketed drug worldwide can be classified as prodrugs. Furthermore, prodrugs designed to be more water soluble launched in the past decade are summarized in a table to have a closer look and finally state that the prodrug design is an amenable approach to increase water solubility.


Assuntos
Pró-Fármacos/química , Água/química , Animais , Desenho de Fármacos , Humanos , Pró-Fármacos/administração & dosagem , Solubilidade , Água/administração & dosagem
5.
Expert Opin Drug Discov ; 12(9): 941-953, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-28664751

RESUMO

INTRODUCTION: There is a great interest in Nitric oxide (NO) within medicinal chemistry since it's involved in human signaling pathways. Prodrugs or hybrid compounds containing NO-donor scaffolds linked to an active compound are valuable, due to their potential for modulating many pathological conditions due to NO's biological properties when released in addition to the native drug. Compounds that selectively inhibit nitric oxide synthase isoforms (NOS) can also increase therapeutic capacity, particularly in the treatment of chronic diseases. However, search for bioactive compounds to efficiently and selectively modulate NO is still a challenge in drug discovery. Areas covered: In this review, the authors highlight the recent advances in the strategies used to discover NO-hybrid derivatives, especially those related to anti-inflammatory, cardiovascular, anticancer and anti-microorganism activities. They also focus on: nitric oxide synthase inhibitors, NO delivery materials and other related activities. Expert opinion: The process of molecular hybridization can be used to obtain NO-releasing compounds that also interact with different targets. The main problem with this approach is to control NO multiple actions in the right biological system. However, the use of NO-releasing groups with many different scaffolds leads to new molecular structures for bioactive compounds, suggesting synergies.


Assuntos
Desenho de Fármacos , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico/metabolismo , Animais , Química Farmacêutica/métodos , Descoberta de Drogas/métodos , Humanos , Óxido Nítrico Sintase/antagonistas & inibidores , Pró-Fármacos , Transdução de Sinais/efeitos dos fármacos
6.
Bioorg Med Chem Lett ; 26(16): 3988-93, 2016 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-27426865

RESUMO

The development of resistance to antibiotics by microorganisms is a major problem for the treatment of bacterial infections worldwide, and therefore, it is imperative to study new scaffolds that are potentially useful in the development of new antibiotics. In this regard, we propose the design, synthesis and biological evaluation of hybrid sulfonylhydrazone bioisosters/furoxans with potential antibacterial (Escherichia coli) activity. The most active compound of the series, (E)-3-methyl-4-((2-tosylhydrazono)methyl)-1,2,5-oxadiazole 2-oxide, with a MIC=0.36µM, was not cytotoxic when tested on Vero cells (IC50>100µM). To complement the in vitro screening, we also studied the interaction of the test compounds with ß-ketoacyl acyl carrier protein synthase (FabH), the target for the parent compounds, and we observed three important hydrogen-bonding interactions with two important active site residues in the catalytic site of the enzyme, providing complementary evidence to support the target of the new hybrid molecules.


Assuntos
Acetiltransferases/antagonistas & inibidores , Antibacterianos/química , Inibidores Enzimáticos/química , Proteínas de Escherichia coli/antagonistas & inibidores , Escherichia coli/enzimologia , 3-Oxoacil-(Proteína de Transporte de Acila) Sintase , Acetiltransferases/metabolismo , Animais , Antibacterianos/síntese química , Antibacterianos/toxicidade , Sítios de Ligação , Candida albicans/efeitos dos fármacos , Domínio Catalítico , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/toxicidade , Escherichia coli/efeitos dos fármacos , Proteínas de Escherichia coli/metabolismo , Ácido Graxo Sintase Tipo II/antagonistas & inibidores , Ácido Graxo Sintase Tipo II/metabolismo , Ligação de Hidrogênio , Testes de Sensibilidade Microbiana , Simulação de Acoplamento Molecular , Oxidiazóis/síntese química , Oxidiazóis/química , Oxidiazóis/toxicidade , Eletricidade Estática , Relação Estrutura-Atividade , Células Vero
7.
Eur J Med Chem ; 121: 553-560, 2016 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-27318979

RESUMO

Chagas disease, caused by Trypanosoma cruzi, is a parasitosis that predominates in Latin America. It is estimated that 25 million people are under the risk of infection and, in 2008, more than 10 thousand deaths were registered. The only two drugs available in the therapeutics, nifurtimox and benznidazole, showed to be more effective in the acute phase of the disease. However, there is no standard treatment protocol effective for the chronic phase. Nitrofurazone (NF), an antimicrobial drug, has activity against T. cruzi, although being toxic. Considering the need for new antichagasic drugs, the existence of promising new therapeutic targets, as 14α-sterol demethylase and cruzain, and employing the bioisosterism and molecular hybridization approaches, four novel compounds were synthesized, characterized by melting point range, elemental analysis, IR and NMR spectroscopy. The compounds were tested against T. cruzi amastigotes in infected U2OS cells. All compounds showed selectivity towards T. cruzi and showed trypanomicidal activity in low micromolar range. The compound 3 showed potency similar to benznidazole, but lower efficacy. These results highlight the importance of the 1,2,4-triazole, thiosemicarbazonic and nitro group moieties for designing new efficient compounds, potentially for the chronic phase of Chagas disease.


Assuntos
Nitrofurazona/síntese química , Nitrofurazona/farmacologia , Triazóis/química , Tripanossomicidas/síntese química , Tripanossomicidas/farmacologia , Trypanosoma cruzi/efeitos dos fármacos , Linhagem Celular Tumoral , Técnicas de Química Sintética , Humanos , Hidrazonas/química , Modelos Moleculares , Conformação Molecular , Nitrofurazona/química , Tripanossomicidas/química
8.
Curr Pharm Des ; 20(27): 4474-85, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24245758

RESUMO

Worldwide, tuberculosis (TB) is the leading cause of death among curable infectious diseases. The emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB is a growing global health concern and there is an urgent need for new anti-TB drugs. Enzymes involved in DNA and ATP biosynthesis are potential targets for tuberculostatic drug design, since these enzymes are essential for Mycobacterium tuberculosis growth. This review presents the current progress and applications of structure-activity relationship analysis for the discovery of innovative tuberculostatic agents as inhibitors of ribonucleotide reductase, DNA gyrase, ATP synthase, and thymidylate kinase enzymes, highlighting present challenges and new opportunities in TB drug design.


Assuntos
Antituberculosos/química , Desenho de Fármacos , Mycobacterium tuberculosis/efeitos dos fármacos , Ácidos Nucleicos/biossíntese , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Antituberculosos/farmacologia , Antituberculosos/uso terapêutico , Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Tuberculose Extensivamente Resistente a Medicamentos/microbiologia , Humanos , Estrutura Molecular , Mycobacterium tuberculosis/enzimologia , Mycobacterium tuberculosis/metabolismo , Relação Quantitativa Estrutura-Atividade , Tuberculose Resistente a Múltiplos Medicamentos/microbiologia
9.
Mol Divers ; 17(4): 711-20, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23990201

RESUMO

Chagas disease and leishmaniasis are neglected tropical diseases, considered as a serious public health. Also, the drugs available for their treatment are toxic and exhibit questionable efficacy. Consequently, the discovery and development of new drug candidates are currently necessary. Dendrimers are highly branched molecules with extremely controlled structure. Those molecular systems display several biological applications (i.e., drug carriers), especially when the focus is prodrug design. Herein, a second generation of dendrimer prodrugs was planned to obtain potentially antichagasic and leishmanicide delivery systems. These dendrimers were composed by myo-inositol (core), L-malic acid (spacer), and three bioactive agents [hydroxymethylnitrofurazone (NFOH), quercetin, 3-hydroxyflavone]. The major aim of this study was to investigate the molecular properties (thermodynamics, steric, steric/electronic, electronic, and hydrophobic) to further describe intersamples relationships through either similarity indices or linear combinations of the original variables. Then, an exploratory data analysis, which comprises hierarchical cluster analysis (HCA) and principal components analysis (PCA), was carried out. Complementary findings were observed for PCA and HCA. Steric, intrinsic/steric, steric/electronic, steric/hydrophobic, hydrophobic, and electronic properties influenced the discrimination process. In addition, these molecular properties can also contribute to enzymatic hydrolysis mechanism elucidation, which depends upon the approximation and a subsequent nucleophilic attack to release the drug from the dendrimer prodrugs.


Assuntos
Antiprotozoários/química , Dendrímeros/química , Desenho de Fármacos , Pró-Fármacos/química , Antiprotozoários/administração & dosagem , Doença de Chagas/tratamento farmacológico , Humanos , Leishmania/efeitos dos fármacos , Modelos Moleculares , Conformação Molecular , Estrutura Molecular , Pró-Fármacos/administração & dosagem , Relação Estrutura-Atividade
10.
J Mol Model ; 18(5): 2257-69, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21965079

RESUMO

A molecular modeling study was carried out to investigate the most likely enzymatic disassembly mechanism of dendrimers that were designed as potential antichagasic and antileishmanial prodrugs. The models contained myo-inositol (core), L-malic acid (spacer), and active agents such as 3-hydroxyflavone, quercetin, and hydroxymethylnitrofurazone (NFOH). A theoretical approach that considered one, two, or three branches has already been performed and reported by our research group; the work described herein focused on four (models A and B), five, or six branches, and considered their physicochemical properties, such as spatial hindrance, electrostatic potential mapping, and the lowest unoccupied molecular orbital energy (E(LUMO)). The findings suggest that the carbonyl group next to the myo-inositol is the most promising ester breaking point.


Assuntos
Dendrímeros/química , Simulação de Dinâmica Molecular , Pró-Fármacos/química , Tripanossomicidas/química , Flavonoides/química , Inositol/química , Malatos/química , Nitrofurazona/análogos & derivados , Nitrofurazona/química , Quercetina/química , Eletricidade Estática , Termodinâmica
11.
J Mol Model ; 17(5): 921-8, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-20607332

RESUMO

Histamine is an important biogenic amine, which acts with a group of four G-protein coupled receptors (GPCRs), namely H(1) to H(4) (H(1)R - H(4)R) receptors. The actions of histamine at H(4)R are related to immunological and inflammatory processes, particularly in pathophysiology of asthma, and H(4)R ligands having antagonistic properties could be helpful as antiinflammatory agents. In this work, molecular modeling and QSAR studies of a set of 30 compounds, indole and benzimidazole derivatives, as H(4)R antagonists were performed. The QSAR models were built and optimized using a genetic algorithm function and partial least squares regression (WOLF 5.5 program). The best QSAR model constructed with training set (N = 25) presented the following statistical measures: r (2) = 0.76, q (2) = 0.62, LOF = 0.15, and LSE = 0.07, and was validated using the LNO and y-randomization techniques. Four of five compounds of test set were well predicted by the selected QSAR model, which presented an external prediction power of 80%. These findings can be quite useful to aid the designing of new anti-H(4) compounds with improved biological response.


Assuntos
Anti-Inflamatórios/química , Benzimidazóis/química , Antagonistas dos Receptores Histamínicos/química , Histamina/metabolismo , Indóis/química , Receptores Histamínicos/química , Algoritmos , Anti-Inflamatórios/metabolismo , Asma/tratamento farmacológico , Asma/fisiopatologia , Benzimidazóis/metabolismo , Desenho de Fármacos , Antagonistas dos Receptores Histamínicos/metabolismo , Humanos , Indóis/metabolismo , Análise dos Mínimos Quadrados , Modelos Químicos , Simulação de Dinâmica Molecular , Relação Quantitativa Estrutura-Atividade , Receptores Histamínicos/metabolismo
12.
Molecules ; 15(5): 3281-94, 2010 May 04.
Artigo em Inglês | MEDLINE | ID: mdl-20657478

RESUMO

Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. The quantitative structure-activity relationship (QSAR) formalisms are among the most important strategies that can be applied for the successful design new molecules. This review provides a comprehensive review on the evolution and current status of 4D-QSAR, highlighting present challenges and new opportunities in drug design.


Assuntos
Desenho de Fármacos , Relação Quantitativa Estrutura-Atividade
13.
J. mol. model ; 17(5): 921-928, July 6, 2010.
Artigo em Inglês | Sec. Est. Saúde SP, SESSP-IBPROD, Sec. Est. Saúde SP, SESSP-IBACERVO | ID: biblio-1063949

RESUMO

Histamine is an important biogenic amine, whichacts with a group of four G-protein coupled receptors(GPCRs), namely H1 to H4 (H1R – H4R) receptors. The actions of histamine at H4R are related to immunological andinflammatory processes, particularly in pathophysiology of asthma, and H4R ligands having antagonistic propertiescould be helpful as antiinflammatory agents. In this work, molecular modeling and QSAR studies of a set of 30compounds, indole and benzimidazole derivatives, as H4R antagonists were performed. The QSAR models were builtand optimized using a genetic algorithm function and partial least squares regression (WOLF 5.5 program). The best QSAR model constructed with training set (N=25) presentedthe following statistical measures: r2=0.76, q2=0.62, LOF=0.15, and LSE=0.07, and was validated using the LNO and y-randomization techniques. Four of five compounds of test set were well predicted by the selected QSAR model, whichpresented an external prediction power of 80%. These findings can be quite useful to aid the designing of newanti-H4 compounds with improved biological response.


Assuntos
Asma/terapia , Receptores de Amina Biogênica/antagonistas & inibidores , Análise dos Mínimos Quadrados
14.
J Comput Aided Mol Des ; 24(2): 157-72, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20217185

RESUMO

Tuberculosis (TB) is the primary cause of mortality among infectious diseases. Mycobacterium tuberculosis monophosphate kinase (TMPKmt) is essential to DNA replication. Thus, this enzyme represents a promising target for developing new drugs against TB. In the present study, the receptor-independent, RI, 4D-QSAR method has been used to develop QSAR models and corresponding 3D-pharmacophores for a set of 81 thymidine analogues, and two corresponding subsets, reported as inhibitors of TMPKmt. The resulting optimized models are not only statistically significant with r(2) ranging from 0.83 to 0.92 and q(2) from 0.78 to 0.88, but also are robustly predictive based on test set predictions. The most and the least potent inhibitors in their respective postulated active conformations, derived from each of the models, were docked in the active site of the TMPKmt crystal structure. There is a solid consistency between the 3D-pharmacophore sites defined by the QSAR models and interactions with binding site residues. Moreover, the QSAR models provide insights regarding a probable mechanism of action of the analogues.


Assuntos
Antituberculosos/química , Inibidores Enzimáticos/química , Mycobacterium tuberculosis/enzimologia , Núcleosídeo-Fosfato Quinase/antagonistas & inibidores , Timidina/análogos & derivados , Algoritmos , Sítios de Ligação/efeitos dos fármacos , Simulação por Computador , Conformação Molecular , Mycobacterium tuberculosis/efeitos dos fármacos , Conformação Proteica , Relação Quantitativa Estrutura-Atividade , Tuberculose/tratamento farmacológico
15.
Arch Pharm (Weinheim) ; 343(2): 91-7, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20099263

RESUMO

Tuberculosis is an infection caused mainly by Mycobacterium tuberculosis. A first-line antimycobacterial drug is pyrazinamide (PZA), which acts partially as a prodrug activated by a pyrazinamidase releasing the active agent, pyrazinoic acid (POA). As pyrazinoic acid presents some difficulty to cross the mycobacterial cell wall, and also the pyrazinamide-resistant strains do not express the pyrazinamidase, a set of pyrazinoic acid esters have been evaluated as antimycobacterial agents. In this work, a QSAR approach was applied to a set of forty-three pyrazinoates against M. tuberculosis ATCC 27294, using genetic algorithm function and partial least squares regression (WOLF 5.5 program). The independent variables selected were the Balaban index (J), calculated n-octanol/water partition coefficient (ClogP), van-der-Waals surface area, dipole moment, and stretching-energy contribution. The final QSAR model (N = 32, r(2) = 0.68, q(2) = 0.59, LOF = 0.25, and LSE = 0.19) was fully validated employing leave-N-out cross-validation and y-scrambling techniques. The test set (N = 11) presented an external prediction power of 73%. In conclusion, the QSAR model generated can be used as a valuable tool to optimize the activity of future pyrazinoic acid esters in the designing of new antituberculosis agents.


Assuntos
Antituberculosos/farmacologia , Modelos Moleculares , Mycobacterium tuberculosis/efeitos dos fármacos , Pirazinamida/análogos & derivados , Algoritmos , Antituberculosos/síntese química , Antituberculosos/química , Desenho de Fármacos , Ésteres , Análise dos Mínimos Quadrados , Testes de Sensibilidade Microbiana , Pró-Fármacos , Pirazinamida/síntese química , Pirazinamida/química , Pirazinamida/farmacologia , Relação Quantitativa Estrutura-Atividade
16.
Arch. pharm ; 343(2): 91-97, Jan 22, 2010.
Artigo em Inglês | Sec. Est. Saúde SP, SESSP-IBPROD, Sec. Est. Saúde SP, SESSP-IBACERVO | ID: biblio-1059804

RESUMO

Tuberculosis is an infection caused mainly by Mycobacterium tuberculosis. A first-line antimycobacterial drug is pyrazinamide (PZA), which acts partially as a prodrug activated by a pyrazinamidase releasing the active agent, pyrazinoic acid (POA). As pyrazinoic acid presents some difficulty to cross the mycobacterial cell wall, and also the pyrazinamide-resistant strains do not express the pyrazinamidase, a set of pyrazinoic acid esters have been evaluated as antimycobacterial agents. In this work, a QSAR approach was applied to a set of forty-three pyrazinoates against M. tuberculosis ATCC 27294, using genetic algorithm function and partial least squares regression (WOLF 5.5 program). The independent variables selected were the Balaban index (J), calculated n-octanol/water partition coefficient (ClogP), van-der-Waals surface area, dipole moment, and stretching-energy contribution. The final QSAR model (N = 32, r2 = 0.68, q2 = 0.59, LOF = 0.25, and LSE = 0.19) was fully validated employing leave-N-out cross-validation and y-scrambling techniques. The test set (N = 11) presented an external prediction power of 73%. In conclusion, the QSAR model generated can be used as a valuable tool to optimize the activity of future pyrazinoic acid esters in the designing of new antituberculosis agents.


Assuntos
Antituberculosos/farmacocinética , Antituberculosos/síntese química , Modelos Moleculares , Mycobacterium tuberculosis , Pirazinamida/análogos & derivados , Algoritmos , Antituberculosos/química
17.
J Mol Graph Model ; 28(1): 3-11, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19376735

RESUMO

Human parasitic diseases are the foremost threat to human health and welfare around the world. Trypanosomiasis is a very serious infectious disease against which the currently available drugs are limited and not effective. Therefore, there is an urgent need for new chemotherapeutic agents. One attractive drug target is the major cysteine protease from Trypanosoma cruzi, cruzain. In the present work, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies were conducted on a series of thiosemicarbazone and semicarbazone derivatives as inhibitors of cruzain. Molecular modeling studies were performed in order to identify the preferred binding mode of the inhibitors into the enzyme active site, and to generate structural alignments for the three-dimensional quantitative structure-activity relationship (3D QSAR) investigations. Statistically significant models were obtained (CoMFA, r2=0.96 and q2=0.78; CoMSIA, r2=0.91 and q2=0.73), indicating their predictive ability for untested compounds. The models were externally validated employing a test set, and the predicted values were in good agreement with the experimental results. The final QSAR models and the information gathered from the 3D CoMFA and CoMSIA contour maps provided important insights into the chemical and structural basis involved in the molecular recognition process of this family of cruzain inhibitors, and should be useful for the design of new structurally related analogs with improved potency.


Assuntos
Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/farmacologia , Modelos Moleculares , Proteínas de Protozoários/antagonistas & inibidores , Relação Quantitativa Estrutura-Atividade , Trypanosoma cruzi/efeitos dos fármacos , Trypanosoma cruzi/enzimologia , Animais , Doença de Chagas/enzimologia , Doença de Chagas/parasitologia , Biologia Computacional , Cisteína Endopeptidases , Humanos , Estrutura Molecular , Análise de Regressão
18.
J Chem Inf Model ; 49(4): 1070-8, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19296716

RESUMO

Thymidine monophosphate kinase (TMPK) has emerged as an attractive target for developing inhibitors of Mycobacterium tuberculosis growth. In this study the receptor-independent (RI) 4D-QSAR formalism has been used to develop QSAR models and corresponding 3D-pharmacophores for a set of 5'-thiourea-substituted alpha-thymidine inhibitors. Models were developed for the entire training set and for a subset of the training set consisting of the most potent inhibitors. The optimized (RI) 4D-QSAR models are statistically significant (r(2) = 0.90, q(2) = 0.83 entire set, r(2) = 0.86, q(2) = 0.80 high potency subset) and also possess good predictivity based on test set predictions. The most and least potent inhibitors, in their respective postulated active conformations derived from the models, were docked in the active site of the TMPK crystallographic structure. There is a solid consistency between the 3D-pharmacophore sites defined by the QSAR models and interactions with binding site residues. This model identifies new regions of the inhibitors that contain pharmacophore sites, such as the sugar-pyrimidine ring structure and the region of the 5'-arylthiourea moiety. These new regions of the ligands can be further explored and possibly exploited to identify new, novel, and, perhaps, better antituberculosis inhibitors of TMPKmt. Furthermore, the 3D-pharmacophores defined by these models can be used as a starting point for future receptor-dependent antituberculosis drug design as well as to elucidate candidate sites for substituent addition to optimize ADMET properties of analog inhibitors.


Assuntos
Desenho de Fármacos , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Núcleosídeo-Fosfato Quinase/antagonistas & inibidores , Tioureia/química , Timidina/análogos & derivados , Timidina/síntese química , Algoritmos , Antituberculosos/síntese química , Antituberculosos/química , Antituberculosos/farmacologia , Inibidores Enzimáticos/síntese química , Ligantes , Modelos Moleculares , Conformação Molecular , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/enzimologia , Relação Quantitativa Estrutura-Atividade , Reprodutibilidade dos Testes , Timidina/farmacologia
19.
J Enzyme Inhib Med Chem ; 23(6): 964-73, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19005945

RESUMO

Chagas' disease is a parasitic infection widely distributed throughout Latin America, with devastating consequences in terms of human morbidity and mortality. Cruzain, the major cysteine protease from Trypanosoma cruzi, is an attractive target for antitrypanosomal chemotherapy. In the present work, classical two-dimensional quantitative structure-activity relationships (2D QSAR) and hologram QSAR (HQSAR) studies were performed on a training set of 45 thiosemicarbazone and semicarbazone derivatives as inhibitors of T. cruzi cruzain. Significant statistical models (HQSAR, q(2) = 0.75 and r(2) = 0.96; classical QSAR, q(2) = 0.72 and r(2) = 0.83) were obtained, indicating their consistency for untested compounds. The models were then used to evaluate an external test set containing 10 compounds which were not included in the training set, and the predicted values were in good agreement with the experimental results (HQSAR, r(2)(pred) = 0.95; classical QSAR, r(2)(pred) = 0.91), indicating the existence of complementary between the two ligand-based drug design techniques.


Assuntos
Cisteína Endopeptidases/metabolismo , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/farmacologia , Relação Quantitativa Estrutura-Atividade , Trypanosoma cruzi/enzimologia , Animais , Inibidores de Cisteína Proteinase/classificação , Concentração Inibidora 50 , Modelos Moleculares , Estrutura Molecular
20.
Bioorg Med Chem ; 16(14): 6724-31, 2008 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-18571927

RESUMO

A series of 53 nitro derivatives rationally designed were obtained by parallel synthesis and screened against Leishmania donovani. Six compounds exhibited IC(50) values lower than standard drugs. Brief SAR analysis revealed that substitution is important to the activity. Nitrothiophene analogues were more potent than the nitrofuran ones. This was attributed to the ability of sulfur atoms in accommodating electrons from nitro group, which facilitate its reduction and therefore the formation of free radicals lethal to parasites.


Assuntos
Compostos Heterocíclicos/química , Leishmania donovani/efeitos dos fármacos , Tripanossomicidas/química , Animais , Radicais Livres , Compostos Heterocíclicos/farmacologia , Concentração Inibidora 50 , Nitrofuranos , Relação Estrutura-Atividade , Tiofenos , Tripanossomicidas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...